Document is current
Any future updates will be listed below
-
Authors
Cho, Soomi https://orcid.org/0000-0003-4723-8975
Chu, Min Kyung https://orcid.org/0000-0001-6221-1346
-
Funding
Funding for this research was provided by:
The Korea Health Industry Development Institute (HV22C0106)
National Research Foundation of Korea (NRF) grant from the Korean government (2022R1A2C1091767)
- License Information
-
More Information
Article History
Accepted: 7 July 2023
First Online: 10 August 2023
Compliance with Ethical Standards
:
: MKC was the site investigator for a multicenter trial sponsored by Biohaven Pharmaceuticals, Allergan Korea, and Ildong Pharmaceutical Company. He has received lecture honoraria from Eli Lilly and Company, Handok-Teva, and Ildong Pharmaceutical Company over the past 24 months. He received grants from the Yonsei University College of Medicine (6–2021-0229) and the Korea Health Industry Development Institute (KHIDI) (HV22C0106) and a National Research Foundation of Korea (NRF) grant from the Korean Government (MSIT) (2022R1A2C1091767). SC declares no conflicts of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
